HK Stock Market Move | VISEN PHARMA-B (02561) rises more than 9% in intraday trading, with its core product, Longpei Growth Hormone, expected to be approved soon.

VISEN PHARMA-B (02561) rose more than 9% during the trading session, and as of the time of writing, it has risen by 7.13% to 37.24 Hong Kong dollars. On the news front, according to Insight database, VISEN PHARMA-B's core product Lonapeptin Growth Hormone left the supplementary material task on January 12, 2026, and is expected to be approved soon. According to publicly available information, Lonapeptin Growth Hormone is a long-acting growth hormone prodrug imported by VISEN PHARMA-B from Ascendis Pharma, developed based on the TransCon temporary connection technology, used to treat children with growth hormone deficiency (GHD), with a weekly subcutaneous injection to release unmodified natural human growth hormone, which has already been approved in Europe and the United States. The domestic growth hormone market is mainly based on daily formulations, and weekly formulations can significantly improve patient compliance. After launching, it is expected to reshape the competitive landscape and meet clinical needs that have not been fully met.